The Chemours Company (CC) investor relations material

Executive summary

• Net sales for Q2 2026 were $1.6 billion, nearly flat year-over-year, as pricing increases offset a 4% volume decline and currency tailwinds.

• Adjusted EBITDA was $247 million, down 5% year-over-year but above expectations, driven by pricing actions and operational discipline.

• Net loss attributable to shareholders was $274 million, improved from a $380 million loss in Q2 2025, mainly due to lower litigation and environmental charges.

• Free cash flow rose 128% year-over-year to $114 million, with conversion at 46% and net leverage reduced to 4.4x.

• Strategic transformation and asset sales supported deleveraging, with significant settlements reducing litigation risk.

Financial highlights

• Q2 2026 net sales were $1.59B, down 1% year-over-year but up $210M sequentially, with gross margin at 18%.

• Adjusted EBITDA margin for Q2 2026 was 15.5%.

• Adjusted net income was $64M, with Adjusted EPS of $0.42; GAAP net loss was $274M, or $(1.81) per share.

• Free cash flow was $114M, up $64M year-over-year; operating cash flow reached $158M, up $65M year-over-year.

Outlook and guidance

• Q3 2026 net sales expected to decrease 5% to flat sequentially; adjusted EBITDA guidance is $175–$205 million.

• Full-year 2026 net sales projected to grow 1–5% over 2025, with adjusted EBITDA of $775–$825 million and free cash flow conversion above 25%.

• Capital expenditures for 2026 expected at $250–$280 million.

• Net leverage ratio targeted at 3.8x by year-end 2026, progressing toward a long-term goal below 3x.